689 related articles for article (PubMed ID: 8497851)
21. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
22. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles.
Rupin A; Martin F; Vallez MO; Bonhomme E; Verbeuren TJ
Thromb Haemost; 2001 Dec; 86(6):1528-31. PubMed ID: 11776323
[TBL] [Abstract][Full Text] [Related]
23. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
24. Fibrin-specific thrombolytic agents.
Collen D
Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
[TBL] [Abstract][Full Text] [Related]
25. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D
Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L
J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity.
Charlton PA; Faint RW; Bent F; Bryans J; Chicarelli-Robinson I; Mackie I; Machin S; Bevan P
Thromb Haemost; 1996 May; 75(5):808-15. PubMed ID: 8725728
[TBL] [Abstract][Full Text] [Related]
28. The role of the finger domain of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in initiation and progression of thrombolysis.
Stringer HA; van Swieten P; Horrevoets AJ; Smilde A; Pannekoek H
Thromb Haemost; 1994 Dec; 72(6):900-5. PubMed ID: 7740461
[TBL] [Abstract][Full Text] [Related]
29. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
30. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
[TBL] [Abstract][Full Text] [Related]
31. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
32. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
Flight SM; Masci PP; Lavin MF; Gaffney PJ
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):417-20. PubMed ID: 16788320
[TBL] [Abstract][Full Text] [Related]
33. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility.
Potter van Loon BJ; Rijken DC; Brommer EJ; van der Maas AP
Thromb Haemost; 1992 Jan; 67(1):101-5. PubMed ID: 1615463
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
35. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole.
Schultze AE; Roth RA
Toxicol Appl Pharmacol; 1993 Jul; 121(1):129-37. PubMed ID: 7687795
[TBL] [Abstract][Full Text] [Related]
36. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
37. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
39. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
Stegnar M; Mavri A
Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
[TBL] [Abstract][Full Text] [Related]
40. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Downing A; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1994 Dec; 58(12):1356-60. PubMed ID: 7528949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
